sorafenib has been researched along with Heart Diseases in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Angus, SP; Beak, JY; Chen, X; Hicks, ST; Huang, W; Jensen, BC; Johnson, GL; Parry, TL; Sciaky, N; Stuhlmiller, TJ; Willis, MS; Zawistowski, JS | 1 |
| Fujita, M; Kuroda, T; Mukai, M; Nakai, Y; Nishimura, K; Oka, T; Shioyama, W; Takada, M; Yasui, T | 1 |
| Biolato, M; Grieco, A; Lombardo, A | 1 |
| Chen, MH | 1 |
| Dudek, AZ; Kamada, P | 1 |
| Force, T; Krause, DS; Van Etten, RA | 1 |
3 review(s) available for sorafenib and Heart Diseases
| Article | Year |
|---|---|
Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Dose-Response Relationship, Drug; Drug Delivery Systems; Female; Heart; Heart Diseases; Heart Failure; Humans; Indoles; Male; Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Risk Assessment; Sorafenib; Sunitinib; Survival Analysis; Trastuzumab | 2009 |
Sorafenib therapy for metastatic renal carcinoma in patients with low cardiac ejection fraction: report of two cases and literature review.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Heart Diseases; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Stroke Volume | 2010 |
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition.
Topics: Adaptor Proteins, Signal Transducing; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Drug Delivery Systems; Enzyme Inhibitors; Heart; Heart Diseases; Humans; Indoles; Lapatinib; Models, Biological; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Trastuzumab | 2007 |
3 other study(ies) available for sorafenib and Heart Diseases
| Article | Year |
|---|---|
Kinome and Transcriptome Profiling Reveal Broad and Distinct Activities of Erlotinib, Sunitinib, and Sorafenib in the Mouse Heart and Suggest Cardiotoxicity From Combined Signal Transducer and Activator of Transcription and Epidermal Growth Factor Recepto
Topics: Animals; Antineoplastic Agents; Cardiotoxicity; Cells, Cultured; Dose-Response Relationship, Drug; Echocardiography; ErbB Receptors; Erlotinib Hydrochloride; Fatty Acids; Female; Gene Expression Profiling; Heart; Heart Diseases; Indoles; Mice; Molecular Targeted Therapy; Myocardial Contraction; Myocardium; Myocytes, Cardiac; Niacinamide; Oxidation-Reduction; Phenylurea Compounds; Protein Interaction Maps; Protein Kinase Inhibitors; Proteomics; Pyrroles; Rats, Sprague-Dawley; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Sunitinib; Time Factors | 2017 |
Aortic Dissection and Cardiac Dysfunction Emerged Coincidentally During the Long-Term Treatment with Angiogenesis Inhibitors for Metastatic Renal Cell Carcinoma.
Topics: Aged; Angiogenesis Inhibitors; Aortic Dissection; Axitinib; Carcinoma, Renal Cell; Heart Diseases; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Lung Neoplasms; Male; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Vascular Endothelial Growth Factor A | 2018 |
Ventricular thrombosis during sorafenib therapy for advanced hepatocellular carcinoma.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Carcinoma, Hepatocellular; Enoxaparin; Heart Diseases; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Protein Kinase Inhibitors; Risk Factors; Sorafenib; Thrombosis; Treatment Outcome; Ultrasonography; Ventricular Dysfunction | 2013 |